ARTICLE | Company News
Cureon, Oxagen deal
December 10, 2001 8:00 AM UTC
Cureon will use its SmArt-Validation target validation platform, which is based on Locked Nucleic Acid (LNA) antisense chemistry technology, to validate Oxagen gene targets. Oxagen also has the right ...